<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723525</url>
  </required_header>
  <id_info>
    <org_study_id>525</org_study_id>
    <secondary_id>NPL-H-SCF</secondary_id>
    <nct_id>NCT03723525</nct_id>
  </id_info>
  <brief_title>Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals</brief_title>
  <acronym>PRAN</acronym>
  <official_title>Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Centre for AIDs and STD Control, Nepal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sukraraj Tropical and Infectious Disease Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Academy of Medical Sciences, Nepal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tribhuvan University Teaching Hospital, Institute Of Medicine.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rapti Sub-regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Western Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seti Zonal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tikapur Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahakali Zonal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bharatpur Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>B.P. Koirala Institute of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Expertise France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Centre for AIDs and STD Control, Nepal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cluster randomized trial to determine whether a package of care including rapid
      antiretroviral therapy (ART) initiation, as compared to standard ART initiation, improves
      mortality, retention in care and viral suppression among treatment naive people living with
      HIV (PLHIV) in Nepal. Package of care includes immediate screening and treatment of
      opportunistic infections (OIs), rapid ART initiation and enhanced retention in care using
      mobile health (mHealth) and weekly/biweekly home-based adherence/ retention support linked to
      community care centre. Standard of care includes screening and management of common OIs,
      baseline assessment (CD4, viral load and other tests), antiretroviral drugs and ART follow
      up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRAN is an open-label trial of 1000 Treatment-Naive PLHIV aged 16 years or more.

        1. To evaluate whether a package of care including rapid ART initiation [diagnosis and
           management of opportunistic infection (OI), rapid ART initiation and enhanced adherence
           support] is more effective in reducing morbidity and mortality, as compared to standard
           ART initiation, among ART naïve PLHIV in Nepal.

        2. To evaluate whether a package of care including rapid ART initiation is more effective
           in improving retention in HIV treatment, as compared to standard ART initiation, among
           ART naïve PLHIV in Nepal.

        3. To evaluate whether a package of care including rapid ART initiation improves viral
           suppression among ART naïve PLHIV in Nepal to a higher extent than standard ART
           initiation,

        4. To evaluate whether the different components of care act synergistically to improve
           mortality, retention in care and viral suppression among treatment Naive PLHIV, as
           compared to standard ART initiation,

        5. To assess the cost-effectiveness of this package of care intervention.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Anticipated">November 29, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Week 24</time_frame>
    <description>All-cause mortality over the first 24 weeks after starting ART</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention in treatment</measure>
    <time_frame>Week 48</time_frame>
    <description>PLHIV alive and on ART over the first 48 weeks after starting ART</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to ART</measure>
    <time_frame>Week 0-48</time_frame>
    <description>Adherence will be assessed on a monthly basis (total pills taken by patient in last month/ total pills prescribed to patient in last month).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Week 48</time_frame>
    <description>Incidence of opportunistic infection and immune reconstitution inflammatory syndrome (IRIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load suppression</measure>
    <time_frame>Week 48</time_frame>
    <description>PLHIV and on ART who have a suppressed viral load (&lt;1000 copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness of Package of care</measure>
    <time_frame>Week 48</time_frame>
    <description>Intervention cost will be calculated from estimates of the per-patient quantity of services used in delivery of package of care. Cost per death prevented and cost per DALY gained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Week 48</time_frame>
    <description>All-cause mortality over the first 96 weeks after starting ART</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>0-48</time_frame>
    <description>Hospital inpatient episodes and total days admitted</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cryptococcal antigen</measure>
    <time_frame>Week 48</time_frame>
    <description>Burden of serum cryptococcal antigen positive in PLHIV with CD4 &lt; 100/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune Reconstitution Inflammatory Syndrome (IRIS)</measure>
    <time_frame>Week 48</time_frame>
    <description>Burden of IRIS</description>
  </other_outcome>
  <other_outcome>
    <measure>CD4 cell count</measure>
    <time_frame>Week 48</time_frame>
    <description>Changes in CD4 cell count</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1073</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Package of HIV care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI), Rapid antiretroviral therapy (ART) initiation and Enhanced adherence support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard HIV care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Screening and management of common OIs, basic health assessment (CD4, viral load and other tests), ARV drugs and follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Package of HIV care</intervention_name>
    <description>A. Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI). Detail information mentioned in the manual (refer to uploaded protocol).
B. Rapid ART Initiation
PLHIV without suspicion or active OI: Initiate ART within seven days or same day after HIV serology disclosure
PLHIV with suspicion or active OI: Defer initiation if clinical symptoms suggest tuberculosis or cryptococcal meningitis. Detail information mentioned in the manual (refer to uploaded protocol).
C. Enhanced Adherence/Retention Support: mHealth: Receive text messages in mobile regarding appointment reminder (pill pick up, CD4 test, viral load test, early infant diagnosis (EID) test etc.) and general awareness messages (positive prevention, the importance of regular health check-up etc.). PLHIV with advanced HIV disease will also receive weekly/biweekly home-based adherence/ retention support linked to community care centre and community home-based care.</description>
    <arm_group_label>Package of HIV care</arm_group_label>
    <other_name>Screening and management of opportunistic infection, Rapid ART initiation and Enhanced adherence support</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Standard HIV care</intervention_name>
    <description>Standard of HIV care includes screening and management of OI (OI- tuberculosis (TB), bacterial pneumonia, herpes, and candidiasis), baseline assessment (CD4 and other blood tests- complete blood count, hemoglobin, platelets, liver function test, renal function test, urine for albumin, chest x-ray), at 6 months CD4 test, viral load (twice a year) and then on a yearly basis, additional lab test at 3 months, 6 months, antiretroviral (ARV) toxicity monitoring like hemoglobin (Zidovudine), Serum Glutamic-Pyruvic Transaminase (Nevirapine/Efavirenz), Creatinine (Tenofovir), prophylaxis (Co-trimoxazole preventive therapy CD4&lt;350 and WHO stage III and IV and Isoniazid preventive therapy if eligible) and ART / follow up (generally monthly/ bimonthly).</description>
    <arm_group_label>Standard HIV care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 16 years

          -  Diagnosed with HIV-infection

          -  ART-naive

          -  Consent for study participation

        Exclusion Criteria:

          -  Age less than or equal to 15 years

          -  Any previous use of ART
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Basu Dev Pandey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre for AIDS and STD Control</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bir B Rawal, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre for AIDS and STD Control</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajan K Bhattarai, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Save the Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajya Shree Nyachhyon Kunwar, MBBS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre for AIDS and STD Control/ Global Fund Programs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Upendra Shrestha, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre for AIDS and STD Control/ Global Fund Programs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajesh Khanal, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre for AIDS and STD Control/ Global Fund Programs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Lagrange-Xelot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Expertise France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tristan Delory, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Expertise France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Mia Ekstrom, MD, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Infectious Diseases Karolinska University Hospital &amp; Dept of Public Health (Global Health/IHCAR), Karolinska Institutet, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tara Nath Pokharel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre for AIDS and STD Control</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keshab Deuba, MMSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre for AIDS and STD Control/ Global Fund Programs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sukraraj Tropical &amp; Infectious Disease Control Hospital</name>
      <address>
        <city>Kathmandu</city>
        <state>Bagmati</state>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bharatpur District Hospital</name>
      <address>
        <city>Bharatpur</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapti Sub Regional Hospital</name>
      <address>
        <city>Dang</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seti Zonal Hospital</name>
      <address>
        <city>Kailālī</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tikapur Hospital</name>
      <address>
        <city>Kailālī</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahakali Zonal Hospital</name>
      <address>
        <city>Kanchanpur</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Academy of Medical Science (NAMS), Bir Hospital</name>
      <address>
        <city>Kathmandu</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tribhuvan University Teaching Hospital</name>
      <address>
        <city>Kathmandu</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Regional Hospital</name>
      <address>
        <city>Pokhara</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B.P. Koirala Institute of Health Sciences</name>
      <address>
        <city>Sunsari</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <reference>
    <citation>Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy. Geneva: World Health Organization; 2017. No abstract available.</citation>
    <PMID>29341560</PMID>
  </reference>
  <reference>
    <citation>INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.</citation>
    <PMID>26192873</PMID>
  </reference>
  <reference>
    <citation>Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD; INSIGHT START study group. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV. 2018 Apr;5(4):e172-e180. doi: 10.1016/S2352-3018(18)30003-1. Epub 2018 Jan 16.</citation>
    <PMID>29352723</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Centre for AIDs and STD Control, Nepal</investigator_affiliation>
    <investigator_full_name>Keshab Deuba</investigator_full_name>
    <investigator_title>Strategic Information Specialist</investigator_title>
  </responsible_party>
  <keyword>Package of care</keyword>
  <keyword>Rapid Initiation of antiretroviral therapy</keyword>
  <keyword>Advanced HIV disease</keyword>
  <keyword>mHealth</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Management of advance HIV disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03723525/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

